Published in Eur J Cancer on May 01, 2004
Development of TLR9 agonists for cancer therapy. J Clin Invest (2007) 2.64
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A (2006) 2.36
Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br J Pharmacol (2012) 1.00
FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer (2014) 0.89
CD9P-1 expression correlates with the metastatic status of lung cancer, and a truncated form of CD9P-1, GS-168AT2, inhibits in vivo tumour growth. Br J Cancer (2011) 0.80
Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells. J Immunol (2015) 0.79
Overexpression of ZNF703 facilitates tumorigenesis and predicts unfavorable prognosis in patients with cholangiocarcinoma. Oncotarget (2016) 0.75
A truncated form of CD9-partner 1 (CD9P-1), GS-168AT2, potently inhibits in vivo tumour-induced angiogenesis and tumour growth. Br J Cancer (2011) 0.75
Clinical predictors of cardiac syncope at initial evaluation in patients referred urgently to a general hospital: the EGSYS score. Heart (2008) 2.85
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol (2008) 2.37
Transvaginal ultrasonography in persistent trophoblastic tumor. Am J Obstet Gynecol (1993) 2.10
Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer (1987) 1.99
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res (1996) 1.60
Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer (1991) 1.58
Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol (1996) 1.55
Intercomparison on the usage of computational codes in radiation dosimetry. Radiat Prot Dosimetry (2004) 1.51
Radiographic findings among children hospitalized with severe community-acquired pneumonia. Pediatr Pulmonol (2010) 1.48
Expression of the monomeric 67-kd laminin-binding protein in human lymphomas as defined by MLuC5 monoclonal antibody and paraffin section immunohistochemistry. Hum Pathol (1995) 1.45
Case report: CMV retinitis in two 10-month-old children with AIDS. J Pediatr Ophthalmol Strabismus (1999) 1.39
Formation of the 67-kDa laminin receptor by acylation of the precursor. J Cell Biochem (1998) 1.34
The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution. Mol Biol Evol (1998) 1.33
Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer (1994) 1.32
Prognostic value of alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells. Clin Cancer Res (1998) 1.29
Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J Natl Cancer Inst (1993) 1.23
Bartonella endocarditis: a pathology shared by animal reservoirsand patients. Ann N Y Acad Sci (2009) 1.21
The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene (1993) 1.21
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol (1998) 1.15
Co-regulation and physical association of the 67-kDa monomeric laminin receptor and the alpha6beta4 integrin. J Biol Chem (1997) 1.13
Overexpression of the 67-kD laminin receptor correlates with tumour progression in human colorectal carcinoma. J Pathol (1996) 1.13
Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res (1993) 1.12
Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer (2006) 1.09
Demonstration of cellular immunity against urethan-induced lung adenomas of mice. J Natl Cancer Inst (1971) 1.09
Genetic analysis of 56 polymorphisms in 17 genes involved in methionine metabolism in patients with abdominal aortic aneurysm. J Med Genet (2008) 1.08
Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification. Int J Cancer (1991) 1.07
Evaluation of conventional and real-time PCR assays for detection and differentiation of Spotted Fever Group Rickettsia in dog blood. Vet Microbiol (2007) 1.07
Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo. Oncogene (2000) 1.07
BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin Cancer Res (2000) 1.06
In vitro demonstration of tumor-specific common antigens and embryonal antigens in murine fibrosarcomas induced by 7,12-dimethylbenz(a)anthracene. Cancer Res (1973) 1.05
Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. Oncogene (1999) 1.04
Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status. Br J Cancer (1991) 1.03
Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol Rep (2000) 1.03
Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis (1993) 1.03
Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene (1998) 1.02
Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res (1993) 1.02
The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. Endocr Relat Cancer (2005) 1.02
An exponential-Gompertzian description of LoVo cell tumor growth from in vivo and in vitro data. Cancer Res (1989) 1.02
Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem (2001) 1.01
Gene expression profiling of peripheral blood in patients with abdominal aortic aneurysm. Eur J Vasc Endovasc Surg (2009) 1.01
Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann Oncol (1994) 1.00
Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression. Clin Exp Metastasis (1992) 0.98
A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer (2001) 0.98
67-Kilodalton laminin receptor expression correlates with worse prognostic indicators in non-small cell lung carcinomas. Clin Cancer Res (1997) 0.96
Production of a monoclonal antibody directed against the recombinant SEL1L protein. Int J Biol Markers (2002) 0.96
A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res (2001) 0.96
Sequences homologous to the mouse mammary tumor virus env gene in human breast carcinoma correlate with overexpression of laminin receptor. Clin Cancer Res (1999) 0.96
Kallmann's syndrome, a neuronal migration defect. Cell Mol Life Sci (2006) 0.96
Natural anti-tumor serum reactivity in BALB/c mice. I. Characterization and interference with tumor growth. Int J Cancer (1977) 0.96
Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res (2001) 0.95
Protein Z-dependent protease inhibitor and protein Z in peripheral arterial disease patients. J Thromb Haemost (2009) 0.95
Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int J Cancer (1988) 0.95
Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab (1992) 0.95
Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res (1996) 0.94
ACE DD genotype: a predisposing factor for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg (2005) 0.94
Urgent carotid endarterectomy in patients with recent/crescendo transient ischaemic attacks or acute stroke. Eur J Vasc Endovasc Surg (2010) 0.94
Probiotic microorganisms: how they affect intestinal pathophysiology. Cell Mol Life Sci (2002) 0.94
Improvement of tumor cell detection using a pool of monoclonal antibodies. Hybridoma (1986) 0.94
Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts. Tumori (1989) 0.93
Early and long-term results of conventional surgical treatment of secondary aorto-enteric fistula. Eur J Vasc Endovasc Surg (2003) 0.93
Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody. Br J Cancer Suppl (1990) 0.93
A multicentre collaborative study on the use of cold scalpel and electrocautery for midline abdominal incision. Am J Surg (2001) 0.93
Expression of the 67 kD laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5. Eur J Cancer (1996) 0.93
Production and characterization of two monoclonal antibodies directed against the integrin beta 1 chain. Tumori (1992) 0.92
A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts. Cancer Res (1999) 0.92
Hepatocyte growth factor/scatter factor facilitates migration of GN-11 immortalized LHRH neurons. Endocrinology (2002) 0.92
Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem (2001) 0.92
67-kDa laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in node-negative breast cancer. Int J Cancer (1995) 0.92
Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J Nucl Med (1997) 0.91
Immunocytochemical identification of breast carcinoma cells in effusions using a monoclonal antibody. J Clin Pathol (1982) 0.91
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. Clin Cancer Res (2013) 0.91
Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells. J Biol Chem (2000) 0.91
Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res (2000) 0.91
Androgen and progesterone metabolism in the central and peripheral nervous system. J Steroid Biochem Mol Biol (1993) 0.91
Influence of eNOS gene polymorphisms on carotid atherosclerosis. Eur J Vasc Endovasc Surg (2004) 0.90
Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. J Natl Cancer Inst (1997) 0.90
Presence of a reduced opioid response in interleukin-6 knock out mice. Eur J Neurosci (1999) 0.90
New developments in antitumor anthracyclines. Pharmacol Ther (1998) 0.89
Preparation and biological evaluation of 4-O-demethyldaunorubicin (carminomycin I) and of its 13-dihydro derivative. J Antibiot (Tokyo) (1978) 0.89
Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int (1997) 0.89
Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety. Chem Biol Interact (1977) 0.88
c-erbB-2 expression in primary breast cancer. Int J Biol Markers (1999) 0.88
Human tumor xenografts in nude mice are not always of human origin. A warning signal. Cancer (1999) 0.88
Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs. Biochem Pharmacol (2001) 0.88
Apoptosis of hair follicle cells during doxorubicin-induced alopecia in rats. Lab Invest (1996) 0.88
Human carcinoma cell lines xenografted in athymic mice: biological and antigenic characteristics of an intraabdominal model. Cancer Immunol Immunother (1987) 0.87
Oral contraceptive use and invasive cervical cancer. Int J Epidemiol (1990) 0.87
Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients. Cancer (1988) 0.87
1975-1995 revised anti-cancer serological response: biological significance and clinical implications. Ann Oncol (1996) 0.87
Evaluation of the suitability of a monoclonal antibody raised against human ovarian carcinoma for therapeutic approaches. Int J Rad Appl Instrum B (1989) 0.87
Detection of Bartonella henselae in the blood of 2 adult horses. J Vet Intern Med (2008) 0.87
The early relapse of premenopausal patients after surgery for node-positive breast carcinoma. Breast Cancer Res Treat (2001) 0.86
The spectrum of 67-kD laminin receptor expression in breast carcinoma progression. J Pathol (1997) 0.86